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INTRODUCTION
Worldwide emergence of multi-drug-resistant tuber-
culosis (MDR TB) has been reported in both developed
and the developing countries and poses a major threat
to the control of TB.1,2 MDR TB, defined as resistance
to at least isoniazid and rifampicin poses a major threat
to tuberculosis control programme, since the treatment
of such cases is complex, more expensive and
frequently less successful than treatment of non-
resistant strains.3 Primary drug resistance is defined as
resistance that develops in a person who has not taken
anti-TB treatment in the past. This is opposed to
acquired drug resistance, which is present in previously
treated patient with inadequate or irregular
chemotherapy. World Health Organization International
Union against tuberculosis and lung disease reported
the prevalence of Primary MDR at 1.4% and 13% in
previously treated patients from a global surveillance for
anti-tuberculosis drug resistance.4 A survey from 48
geographic sites revealed that drug resistant
tuberculosis is ubiquitous and median prevalence of
primary resistance to at least one drug is around 10.7%
and that of Primary MDR only 1%.5
In Pakistan, the incidence of TB is estimated at 181/
100,000 population and each year at least 286,000 new
TB cases are added to the existent patient population of
around 1.8 million.6 The level of drug resistance is
known to provide an epidemiological indicator to assess
the extent of resistant bacterial transmission in the
community as well as success or otherwise of National
Tuberculosis Programme (NTP). High levels of
resistance have been reported in certain regions of the
world particularly in Asia and parts of Africa.7-13 Several
countries in Asia and Africa undertook national surveys
to see the prevalence of drug resistance. Countries
including Tanzania, South Africa and India established
systematic national surveillance programmes.14-16 In
Pakistan, no such survey has ever been carried out. In
a country ranked 6th in the world in terms of TB disease
burden and with 45% of TB disease burden of EMRO
region, resistance surveillance studies are required to
determine the frequency, prevalence, pattern and trends
of anti-TB drug resistance in the country.
The DOTS strategy has only been recently implemented
in the country and TB patients by and large have been
treated unsupervised. It was assumed that primary drug
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resistance is likely to be high in Pakistan. This
hypothesis was supported by reports from different
cities of Pakistan pointing towards a high drug
resistance in the country, one study showed resistance
to rifampicin (R) and isoniazid (INH) to 15% and 11%
respectively17 and in another one, resistance to H 25%,
R 15%, ethambutol (E) 12% and S 12%.18 A study from
NWFP in 1994 also showed relatively high primary and
acquired drug resistance.19
The aim of this study was to determine the frequency of
primary anti-tuberculous drug resistance in the city of
Karachi.    
METHODOLOGY
The study was approved by Research and Ethics
Committee of Postgraduate Medical Institute, Peshawar,
Pakistan. The study was designed to determine
resistance of Mycobacterium tuberculosis isolates from
sputum cultures of newly-diagnosed, smear-positive TB
patients, which were collected from patients of Karachi
presenting with features of TB to diagnostic centres from
April to December 2005. 
The centres where all the 4 investigators worked in
different parts of the city formed the diagnostic centres.
These included TB control programme centres, out-
patient departments of JPMC, Liaqat National Hospital,
Ojah Institute of Chest Diseases, Lyari General Hospital
and private clinics of all the investigators.
Subjects’ sputum smear examination was performed at
the respective diagnostic centres, where the patients
suspected to have TB were screened. The subjects with
smear-positive specimens were enrolled in the study
and their sputum were sent to the collection centre of
the central laboratory for culture and sensitivity testing
provided the patient has not used anti-TB treatment in
the past and fulfilled all the inclusion criteria.
The sample size was calculated according to the
population and World Health Organization’s (WHO)
estimated incidence of smear-positive tuberculosis in
the country. Accordingly, a sample size of at least 140
was needed for the study, which was collected over a
period of 6 months. A sputum specimen in the container
provided by the central laboratory along with a form was
filled by the investigator at the diagnostic centre, giving
beside other details a declaration by the investigator that
he has confirmed that the patient has never taken anti-
TB drugs in the past. Patients were given an information
leaflet and informed consent was taken from all patients.
Inclusion criteria were new smear-positive pulmonary
TB patients, resident of Karachi, with no prior anti-TB
medication, whose sputum were collected for culture
before start of treatment. Patients who had used some
form of anti-TB treatment in the past were excluded.
The Department of Microbiology Laboratory at Aga
Khan University Hospital was used as the central
laboratory for culture and sensitivity testing. Smears for
microscopy were screened using Auramine Rhodamine
staining. Positive slides were further confirmed by
staining with kinyoun modification of Ziehl Nelson stain.
Mycobacterial cultures were performed on both liquid as
well as solid media. Sediments were cultured at 370C
using Lowenstein Jensen (LJ) medium and MIGIT. For
LJ slant 0.1 ml of concentrated specimen was
inoculated and incubated for 8 weeks. MGIT vials were
inoculated with 0.5 ml of specimen and incubated at
370C after supplementation of medium with OADC and
PANTA: containing polymyxin B, amphotericin B,
nalidixic acid, trimethoprim and azlocilin. Growth from
the positive LJ slant, and MGIT vials were first stained
with Kinyoun and M. tuberculosis was identified by
BACTEC NAP TB differentiation test.
Susceptibility testing was performed using standard
agar proportion method on enriched Middle Brook 7H 10
medium at the following final drug concentration;
rifampicin 5 ug/ml, isoniazid 1 ug/ml, streptomycin
10 ug/ml and ethambutol 10 ug/ml.20,21 Disc elusion
sensitivity plates were prepared using paper sensitivity
disc. McFarland No. 1 standard suspension of isolate
was made from growth on LJ slant and  diluted to 10-2
and 10-4 dilutions. The inoculated plates were incubated
at 350C and examined for growth >1% above the
antibiotic free control was observed in drug containing
area. Pyrazinamide sensitivity was carried out 100 g/ml
(BACTEC using the BACTEC 7H 12 medium pH 6.0 at
100TM PZA test medium in accordance with
susceptibililty testing.
Data was analyzed using SPSS version 10.
RESULTS
One hundred and forty samples collected from eight
centres were evaluated, out of which 131 (93.5%)
samples were found to be culture-positive. 
On smear examination, 7 (5.3%) of 131 smear-positive
specimens collected from diagnostic centres from
across the province were found to be smear-negative at
the reference laboratory.
Drug susceptibility tests were positive in samples. One
sample grew Mycobacterium other than Tuberculosis
(MOTT) and hence was excluded from further analysis.
Out of the remaining 130 patients, the isolates from 115
(88.4%) patients were fully susceptible to all the 1st line
drugs tested, while 15 (11.5%) patients showed
resistance to one or more drugs. Resistance to Isoniazid
(H) alone or in combination with other drugs was seen in
12 (9.2%) patients. Similarly, resistance to Streptomycin
(S), Rifampicin (R), Ethambutol (F) and Pyrazinamide
(P) was seen in 8 (6.1%), 4 (3%), 1 (0.76) and 6 (4.6)
respectively (Table I). 
Resistance to one drug was seen in 10 (7.6%) patients,
2 drugs in none of the patients, 3 drugs in 4 (3%)
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patients, 4 drugs in one (0.76%) patients and one
(0.76%) sample showed resistance to all the 5 drugs.
Primary MDR was found in 2 (1.5%) patients (Table II).
DISCUSSION
The WHO/IUATLD Global Project on anti-tuberculosis
drug resistance surveillance recorded considerable
variation in the prevalence of drug resistance among 35
countries in 5 continents. The median prevalence of
Primary drug resistance was 9.9% with range of 2-41%.
Overall, the median prevalence of primary MDR-TB was
1.4% ranging from 0-10%. Among the South East Asian
Region (SEAR) countries, the prevalence or primary
resistance is readily available only for Nepal and
Thailand since they participated in the WHO supported
Global Project on Anti-tuberculosis Drug Resistance
Surveillance in 1994-97. The median prevalence of
acquired resistance to any drug was recorded as 23.2%
with range of 9.8-36.6%. The median prevalence of
primary MDR-TB was 2.5% significantly higher than the
global mean of 1.4%.3
This study revealed culture positively of over 90% of all
the smear-positive patients. The level of drug resistance
to isoniazid, rifampicin, and MDR of 9.2%, 3%, and 1.5%
respectively in previously untreated cases, as is evident
from this study, is not as high as one would have
expected, keeping in view that Karachi has recently
reached the WHO target of 100% DOTS coverage.
These values are comparable with resistance studies in
different 3rd world countries. However, the result of this
study is different from other surveys conducted in
Pakistan. According to a study by Khan, et al. the primary
resistance to isoniazid and rifampicin was found to be
11% and 15% respectively.17 In another study,
resistance was found to be even higher with H 25%, R
15%, E 12% and S 19%.18 The relatively high
percentage of resistance to individual drugs in studies
from Pakistan was perhaps due to the faulty selection of
patients and it appears that efforts were not made to
separate primary drug resistance from initial or acquired
resistance.22,23 There is a strong need to evaluate the
primary resistance  to anti-tuberculosis drugs in various
provinces and the whole country.
Strong TB control programme with DOTS strategy can
control the emergence of drug resistance in the
community. Since no newer drugs for tuberculosis are
likely to become available in the near future, the only
options left for the prevention of drug resistance are
effective case finding, prompt and correct diagnosis and
successful treatment of patients. Apart from a strong
control programme, continuous surveillance of drug
resistance will provide information, which will serve as a
useful parameter in the evaluation of control
programme.
CONCLUSION
This study shows that although the frequency of Primary
MDR-TB was 11.5%, implementation of DOTS strategy
is required to prevent the generation of resistant strains.
A poorly functioning programme can create MDR-TB
much faster than it can be treated, even if unlimited
resources are available. 
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